Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe Esketamine's Mind-Altering side effects

NCT ID NCT06133309

Knowledge-focused Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study looked at 15 people with depression who experienced temporary dissociative states (feeling disconnected from reality) while taking Esketamine. Researchers used interviews to understand these experiences better. The goal is to learn more about this side effect to improve treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Esketamine
What this could lead to
If successful, this could help doctors better understand and manage the dissociative side effects of Esketamine, potentially improving treatment for depression.
What could go wrong
This is a very small, completed study (15 people) that only observes and describes experiences. It does not test a new treatment, so it may not lead to direct changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Mar 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient followed in the Psychiatry Department of Hôpital Sainte Musse, with depressive state characterized by the DSM-V criteria and treated with Esketamine between 2 days and 3 months prior to the study; * Patient over the age of 18; * Patient presented transient dissociative state during Esketamine treatment; * Patient able to express his/her consent prior to participation in the study; * Patient who understands and speaks French. Exclusion Criteria: * Patient with major anxiety and panic attack during an Esketamine-induced dissociative state, regardless of Esketamine effect; * Patient under judicial protection (guardianship, curatorship...) or safeguard of justice; * Pregnant, parturient or breast-feeding women; * Any other reason that, in the opinion of the investigator, would interfere with the evaluation of the study objectives.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depressive disorder

Contacts and locations

Locations

  • Centre Hospitalier Intercommunal Toulon La Seyne sur Mer

    Toulon, Var, 83100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.